Amgen 2010 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Serving Patients and Strengthening the Communities
in Which We Operate
Products and Partnerships
• Two Amgen therapeutics—Prolia® (denosumab) and XGEVA™
(denosumab)—were approved in 2010. Prolia® was approved in the
United States, Europe, Canada, Australia, and Switzerland. In the
United States, Prolia® was approved for the treatment of postmenopausal
women with osteoporosis who are at high risk for fracture. XGEVA™
received FDA approval for the prevention of skeletal-related events in
patients with bone metastases from solid tumors. For more on these
products and denosumab’s path from discovery to market, see page 6.
• Amgen continued its sponsorship of the Amgen Tour of California and
the company’s Breakaway from Cancer ® initiative for the fi fth consecutive
year. Breakaway from Cancer ® continues to be Amgen’s signature
oncology initiative that raises awareness of the valuable support, education,
and advocacy resources available to those affected by cancer.
• As part of an ongoing commitment to the advancement of cancer
treatments, Amgen continued to support Stand Up To Cancer (SU2C).
• Amgen continued its partnership with the National Osteoporosis
Foundation and the Society for Women’s Health Research on Know My
Bones, a program that educates women on the importance of managing
their osteoporosis.
• Amgen and Pfi zer also continued the Addressing Psoriasis™ campaign,
teaming with style guru Tim Gunn. The campaign was developed to inspire
people with plaque psoriasis to actively manage their condition, become
more confi dent, and not allow the condition to inhibit their everyday life.
• In addition, Amgen and Pfi zer announced a partnership with Phil Mickelson,
a world-class professional golfer with psoriatic arthritis and an Enbrel®
(etanercept) patient.
Philanthropy, Community, and Environment
• Amgen and the Amgen Foundation gave more than a quarter billion
dollars through Foundation grants, corporate giving, and product donations.
Amgen staff in Breda, the Netherlands,
stand proudly with one of the fi rst shipments
of Prolia® to patients.